Why This Stage of Prostate Cancer Is So Difficult
Prostate cancer is driven by testosterone. When it spreads, doctors use hormone treatments to cut testosterone levels as low as possible. For many men, this works — for a while.
But in some cases, the cancer adapts and keeps growing even without testosterone. That is when it becomes "castration-resistant," and it is the hardest form to treat. The men in this study had already received at least one of the standard drugs used at this stage. Their cancer had kept moving.
Two Different Weapons, One Plan
Researchers combined two drugs that work through completely different mechanisms.
The first, olaparib, is a type of drug called a PARP inhibitor. Here is the simple version: some cancer cells have a broken DNA repair system. They cannot fix damage to their own DNA the normal way. So they depend on a backup repair pathway — one that uses a protein called PARP. Block PARP, and those cancer cells have nowhere left to turn. They can not fix themselves and they die. This approach works especially well when the cancer carries specific DNA repair gene variants, which make the backup pathway even more essential.
The second drug, durvalumab, is an immunotherapy. Cancer cells sometimes wave a chemical "don't attack me" signal at the immune system, telling T cells to stand down. Durvalumab blocks that signal, essentially ripping down the flag so immune cells can see the cancer and go after it.
The idea: olaparib weakens the cancer from the inside, while durvalumab calls in the immune system to finish the job.
What the Study Looked Like
This was a phase 2 clinical trial — an early test of whether the combination works well enough to study further. Sixty-one men with metastatic castration-resistant prostate cancer were enrolled. All had previously received standard hormone-blocking treatments that had stopped working. Researchers took biopsies when possible, and tracked blood markers — including circulating tumor DNA, a kind of liquid biopsy that detects cancer DNA floating in the bloodstream — to understand who was responding and why.
There was no comparison group.
The Results: Modest Overall, Striking for Some
For the full group, the combination kept the cancer from visibly progressing on scans for a median of about 5 months. That is a meaningful number in a heavily pretreated population, but it is not dramatic. About 10 men had a measurable tumor response, and roughly one in four saw their PSA levels drop by at least half — a sign of at least some anti-cancer activity.
Here is where things get interesting.
When researchers looked at the men whose tumors carried HRR gene variants — meaning their cancer had a broken DNA repair system — the picture changed sharply. That subgroup went a median of more than 13 months before their cancer progressed on scans, compared to about 4.8 months for men whose tumors did not carry those variants. That is a large difference, and it was statistically meaningful.
The liquid biopsy data pointed the same direction: men with higher levels of cancer DNA in their blood at the start of treatment tended to do worse. More tumor burden meant less time before things got harder.
Where This Fits in the Bigger Picture
This is not an isolated finding. Across cancer research, the same pattern keeps emerging: combinations show incremental results in broad populations, but matching the right treatment to the right biology can produce striking benefits. This study adds another data point to that story.
This combination is not available outside of clinical trials right now. It is an experimental regimen, and the findings here are exploratory. But they do support the idea that testing a patient's tumor for DNA repair gene variants matters — because that information may eventually guide which treatment approach makes the most sense.
Limitations Worth Knowing
This study was small — 61 patients — and had no control group, so it is not possible to say with certainty how much of the benefit came from the combination versus what might have happened with either drug alone. Some of the blood-based findings, including the immune cell patterns and gene expression markers tied to outcomes, are exploratory and need to be confirmed in larger studies. The follow-up time was limited.
What Comes Next
These findings are likely to push researchers toward future trials that enroll only patients with HRR gene variants — the group that benefited most. Understanding why some patients respond while others do not, and refining predictive tools like liquid biopsies, is the work ahead. Larger, controlled trials will be needed before this combination could move toward standard use.
Would you consider genetic testing of your cancer's DNA repair genes if it might help your doctor choose the right treatment?
- How DNA Repair Gene Variants Affect Cancer Treatment
- What to Know About PARP Inhibitors in Prostate Cancer
- Understanding Immunotherapy: How It Works Against Cancer
